Literature DB >> 14684825

Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays.

Jason M Johnson1, John Castle, Philip Garrett-Engele, Zhengyan Kan, Patrick M Loerch, Christopher D Armour, Ralph Santos, Eric E Schadt, Roland Stoughton, Daniel D Shoemaker.   

Abstract

Alternative pre-messenger RNA (pre-mRNA) splicing plays important roles in development, physiology, and disease, and more than half of human genes are alternatively spliced. To understand the biological roles and regulation of alternative splicing across different tissues and stages of development, systematic methods are needed. Here, we demonstrate the use of microarrays to monitor splicing at every exon-exon junction in more than 10,000 multi-exon human genes in 52 tissues and cell lines. These genome-wide data provide experimental evidence and tissue distributions for thousands of known and novel alternative splicing events. Adding to previous studies, the results indicate that at least 74% of human multi-exon genes are alternatively spliced.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684825     DOI: 10.1126/science.1090100

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  599 in total

1.  Centromere-associated protein E expresses a novel mRNA isoform in acute lymphoblastic leukemia.

Authors:  Cindy E Jiménez-Ávila; Vanessa Villegas-Ruíz; Marta Zapata-Tarres; Alejandra E Rubio-Portillo; Eleazar I Pérez López; Juan C Zenteno; Sergio Juárez-Méndez
Journal:  Int J Mol Epidemiol Genet       Date:  2018-10-20

2.  Human corin isoforms with different cytoplasmic tails that alter cell surface targeting.

Authors:  Xiaofei Qi; Jingjing Jiang; Mingqing Zhu; Qingyu Wu
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

3.  ASmodeler: gene modeling of alternative splicing from genomic alignment of mRNA, EST and protein sequences.

Authors:  Namshin Kim; Seokmin Shin; Sanghyuk Lee
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

4.  A non-EST-based method for exon-skipping prediction.

Authors:  Rotem Sorek; Ronen Shemesh; Yuval Cohen; Ortal Basechess; Gil Ast; Ron Shamir
Journal:  Genome Res       Date:  2004-08       Impact factor: 9.043

5.  Over 20% of human transcripts might form sense-antisense pairs.

Authors:  Jianjun Chen; Miao Sun; W James Kent; Xiaoqiu Huang; Hanqing Xie; Wenquan Wang; Guolin Zhou; Run Zhang Shi; Janet D Rowley
Journal:  Nucleic Acids Res       Date:  2004-09-08       Impact factor: 16.971

6.  In vivo effects on intron retention and exon skipping by the U2AF large subunit and SF1/BBP in the nematode Caenorhabditis elegans.

Authors:  Long Ma; Zhiping Tan; Yanling Teng; Sebastian Hoersch; H Robert Horvitz
Journal:  RNA       Date:  2011-10-27       Impact factor: 4.942

7.  Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation.

Authors:  Min Yang; Jack Wu; Si-Hung Wu; An-Ding Bi; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

8.  Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Authors:  Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar
Journal:  Ann Med       Date:  2020-08-24       Impact factor: 4.709

9.  Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene.

Authors:  Jin Xu; Mingming Xu; Yasmin L Hurd; Gavril W Pasternak; Ying-Xian Pan
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

10.  A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart.

Authors:  Auinash Kalsotra; Xinshu Xiao; Amanda J Ward; John C Castle; Jason M Johnson; Christopher B Burge; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.